Advertisement
Brief report| Volume 40, ISSUE 6, P547-549, September 15, 1996

Intranasal oxytocin in obsessive-compulsive disorder

DOI:https://doi.org/10.1016/0006-3223(96)00120-5
Intranasal oxytocin in obsessive-compulsive disorder
Previous ArticleHeadache response to m-chlorophenylpiperazine in obsessive-compulsive disorder and normal controls
Next ArticleEffect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic
      This paper is only available as a PDF. To read, Please Download here.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • American Psychiatric Association, Committee on Nomenclature and Statistics
        4th ed. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Press, New York1994
        • Anssean M
        • Legros JJ
        • Mormont C
        • et al.
        Intranasal oxytocin in obsessive compulsive disorder.
        Psychoneuroendocrinology. 1987; 12: 231-236
        • Bohus B
        • Kovacs GL
        • De Wied D
        Oxytocin, vasopressin and memory.
        Brain Res. 1978; 157: 414-417
        • Charles G
        • Guillaume R
        • Schittecatte M
        • Pholien P
        • Van Wettere JP
        • Wilmotte J
        Oxytocin in the treatment of obsessive-compulsive disorder: A report on two cases.
        Psychiatry Psychobiol. 1989; 4: 111-115
        • Den Boer JA
        • Westenberg HGM
        Oxytocin in obsessive compulsive disorder.
        Peptides. 1992; 13: 1083-1085
        • Epperson CN
        • McDougle CJ
        • Brown RM
        • Price LH
        Obsessive compulsive disorder during pregnancy and the puerperium.
        American Psychiatric Association New Rearch Abstract #NR112. 1995; (May 22): 84
        • Goodman WK
        • Price LH
        • Delgado PL
        • et al.
        Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder.
        Arch Gen Psychiatry. 1990; 47: 577-585
        • Insel TR
        Oxytocin—A neuropeptide for affiliation: Evidence from behavioral, receptor autoradiographic and comparative studies.
        Psychoneuroendocrinology. 1992; 17: 3-35
        • Kaltwasser TM
        • Crawley JN
        Oxytocin and cholecystokinin induce grooming behavior in the ventral tegmentum of the rat.
        Brain Res. 1987; 426: 1-7
        • Leckman JF
        • Goodman WK
        • North WC
        • et al.
        The role of central oxytocin in obsessive compulsive disorder and related normal behavior.
        Psychoneuroendocrinology. 1994; 19: 723-749
        • Leckman JF
        • Goodman WK
        • North WC
        • et al.
        Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder: Comparison with Tourette's syndrome and healthy controls.
        Arch Gen Psychiatry. 1994; 51: 782-792
        • Mazurek MF
        • Beal MF
        • Bird ED
        • Marin JB
        Oxytocin in alzheimer's disease: Postmortem brain levels.
        Neurology. 1987; 37: 1001-1003
        • Pedersen CA
        • Prange AJ
        Induction of maternal behaviour in virgin rats after intracerebroventricular administration of oxytocin.
        in: Proc Natl Acad Sci USA. 76. 1979: 6661-6665
        • Salzberg AD
        • Swedo SE
        Oxytocin and vasopressin in obsessive-compulsive disorder.
        Am J Psychiatry. 1992; 149: 713-714

      Article info

      Publication history

      Received in revised form: February 21, 1996
      Received: October 18, 1995

      Footnotes

      This work was supported by a National Alliance for the Research on schizophrenia and Depression Young Investigator Award (Drs. Epperson and McDougle), the Stanley Foundation (Dr. Price), the State of Connecticut Department of Mental Health, and the National Institutes of Health grants PO1 MH25642 and T32 MH 18268.

      Identification

      DOI: https://doi.org/10.1016/0006-3223(96)00120-5

      Copyright

      © 1996 Society of Biological Psychiatry. Published by Elsevier Inc.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX